OBJECTIVE: Serpins (serine protease inhibitors) are associated with protection against HIV infection. Here, we characterized mucosal serpin expression in the genital tract of HIV highly exposed sero-negative (HESN) women meeting our epidemiological definition of HIV resistance in relation to epidemiological variables. METHODS: Cervicovaginal lavage (CVL) fluid and plasma were collected from 84 HIV-resistant, 54 HIV-uninfected, and 66 HIV-infected female commercial sex workers. Serpin A1 and A3 concentrations were measured by ELISA and compared with clinical information. RESULTS: Mucosal serpin A1 was elevated during proliferative phase over secretory phase (P = 0.017*), while A3 remained similar (P = 0.25). Plasma and mucosal serpin A1/A3 levels were not associated with each other and appeared compartment specific (r = 0.21, r = 0.056). Serpin A1/A3 expression did not associate with age (r = 0.009, r = -0.06), duration of sex work (r = 0.13, r = -0.10), clients per day (r = -0.11, r = -0.02), concurrent STIs (P = 0.36, P = 0.15), but was lower in women using hormonal contraceptives (P = 0.034, P = 0.008). Mucosal serpin A1/A3 levels in HIV-infected individuals were not significantly different with disease status as determined by plasma CD4(+) T-cell counts (P = 0.94, P = 0.30). CONCLUSION: This study shows the relationship of serpins to the menstrual cycle and hormonal contraceptives, as well as their independence to epidemiological sexual confounders. This information provides a broader understanding of innate components of the mucosal immune system in women.
OBJECTIVE: Serpins (serine protease inhibitors) are associated with protection against HIV infection. Here, we characterized mucosal serpin expression in the genital tract of HIV highly exposed sero-negative (HESN) women meeting our epidemiological definition of HIV resistance in relation to epidemiological variables. METHODS: Cervicovaginal lavage (CVL) fluid and plasma were collected from 84 HIV-resistant, 54 HIV-uninfected, and 66 HIV-infected female commercial sex workers. Serpin A1 and A3 concentrations were measured by ELISA and compared with clinical information. RESULTS: Mucosal serpin A1 was elevated during proliferative phase over secretory phase (P = 0.017*), while A3 remained similar (P = 0.25). Plasma and mucosal serpin A1/A3 levels were not associated with each other and appeared compartment specific (r = 0.21, r = 0.056). Serpin A1/A3 expression did not associate with age (r = 0.009, r = -0.06), duration of sex work (r = 0.13, r = -0.10), clients per day (r = -0.11, r = -0.02), concurrent STIs (P = 0.36, P = 0.15), but was lower in women using hormonal contraceptives (P = 0.034, P = 0.008). Mucosal serpin A1/A3 levels in HIV-infected individuals were not significantly different with disease status as determined by plasma CD4(+) T-cell counts (P = 0.94, P = 0.30). CONCLUSION: This study shows the relationship of serpins to the menstrual cycle and hormonal contraceptives, as well as their independence to epidemiological sexual confounders. This information provides a broader understanding of innate components of the mucosal immune system in women.
Authors: Andrea Ries Thurman; Neelima Chandra; Nazita Yousefieh; Irina Zalenskaya; Thomas Kimble; Susana Asin; Christiane Rollenhagen; Sharon M Anderson; Betsy Herold; Pedro M M Mesquita; Nicola Richardson-Harman; Tina Cunningham; Jill L Schwartz; Gustavo F Doncel Journal: AIDS Res Hum Retroviruses Date: 2016-02-10 Impact factor: 2.205
Authors: S A Vishwanathan; A Burgener; S E Bosinger; G K Tharp; P C Guenthner; N B Patel; K Birse; D L Hanson; G R Westmacott; T R Henning; J Radzio; J G Garcia-Lerma; T B Ball; J M McNicholl; E N Kersh Journal: J Virol Date: 2015-06-24 Impact factor: 5.103
Authors: Kenzie Birse; Kelly B Arnold; Richard M Novak; Stuart McCorrister; Souradet Shaw; Garrett R Westmacott; Terry B Ball; Douglas A Lauffenburger; Adam Burgener Journal: J Virol Date: 2015-06-17 Impact factor: 5.103
Authors: Kenzie D M Birse; Amy L Cole; Taha Hirbod; Lyle McKinnon; Terry B Ball; Garrett R Westmacott; Joshua Kimani; Frank Plummer; Alexander M Cole; Adam Burgener; Kristina Broliden Journal: PLoS One Date: 2015-06-19 Impact factor: 3.240
Authors: S Mukhopadhyay; Y Liang; H Hur; G Villegas; G Calenda; A Reis; L Millen; P Barnable; L Mamkina; N Kumar; T Kalir; R Sperling; N Teleshova Journal: Sci Rep Date: 2019-09-17 Impact factor: 4.379
Authors: Laura M Romas; Klara Hasselrot; Lindsay G Aboud; Kenzie D Birse; T Blake Ball; Kristina Broliden; Adam D Burgener Journal: PLoS One Date: 2014-06-30 Impact factor: 3.240
Authors: Juliana Reis Machado; Marcos Vinícius da Silva; Camila Lourencini Cavellani; Marlene Antônia dos Reis; Maria Luiza Gonçalves dos Reis Monteiro; Vicente de Paula Antunes Teixeira; Rosana Rosa Miranda Corrêa Journal: Biomed Res Int Date: 2014-09-15 Impact factor: 3.411